Sanjay Singh
Interventional Cardiology · Waukesha, WINPI 1922072248
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,200 of the $46,081 with a category attached, or 82.9%. Johnson & Johnson accounts for 86.7% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $35,736 and has fallen 99.9% since, to $26 in 2022. Among interventional cardiology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $168.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$40K
- Lilly USA, LLC$2K
- AstraZeneca$712
- Pfizer$578
- Boehringer Ingelheim$423
- Astellas Pharma US Inc$234
- plus $2K from 24 others
Across 2 payments — averaging $3410.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$7K
- Amgen$77
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$38,20083%
- Travel & lodging$2,2555%
- Food & beverage$5,10511%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 83 | $39,946 |
| Lilly USA, LLC | 1 | $2,200 |
| AstraZeneca | 32 | $712 |
| Pfizer | 28 | $578 |
| Boehringer Ingelheim | 21 | $423 |
| Astellas Pharma US Inc | 4 | $234 |
| Amgen | 13 | $233 |
| Daiichi Sankyo Inc. | 8 | $186 |
| Regeneron Healthcare Solutions, Inc. | 10 | $179 |
| Gilead | 7 | $166 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 7 | $133 |
| Kowa Pharmaceuticals America, Inc. | 9 | $122 |
| Boston Scientific | 5 | $115 |
| Philips North America LLC | 1 | $104 |
| Lundbeck LLC | 6 | $91 |
| Amarin Pharma, Inc. | 5 | $91 |
| Novartis | 6 | $86 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Portola Pharmaceuticals, LLC | 3 | $73 |
| United Therapeutics Corporation | 4 | $58 |
| Novo Nordisk | 3 | $51 |
| Bard Peripheral Vascular, Inc. | 2 | $48 |
| Bardy Diagnostics, Inc. | 3 | $30 |
| Terumo Medical Corporation | 1 | $26 |
| Abbott | 1 | $23 |
| Angiodynamics, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Biocompatibles, Inc. | 1 | $18 |
| Braemar Manufacturing, LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$38,682
- EFFIENT$2,200
- VYNDAQEL$243
- FARXIGA$242
- JARDIANCE$125
- Turbo Elite$104
How this compares
$46,081 in reported general payments places this provider in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Waukesha
- Lisa SchmitzWaukesha$12K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
- Iyad AzzamMilwaukee$60K
- Mark HoffmannWausau$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.